-
公开(公告)号：EP3512562B1
公开(公告)日：2021-06-30
申请号：EP17777504.6
申请日：2017-09-15
-
公开(公告)号：EP3609493A1
公开(公告)日：2020-02-19
申请号：EP18716578.2
申请日：2018-04-03
申请人： Adamed Pharma S.A.
IPC分类号： A61K31/4178 , A61K31/4164 , A61K31/7048 , A61K45/06 , A61K9/00 , A61K9/20 , A61K47/06 , A61P31/04
-
公开(公告)号：EP3749286B1
公开(公告)日：2024-10-23
申请号：EP19702616.4
申请日：2019-02-02
IPC分类号： A61K9/16 , A61K31/4152 , A61K31/472 , A61K31/522 , A61K9/24
-
公开(公告)号：EP4420664A1
公开(公告)日：2024-08-28
申请号：EP23158767.6
申请日：2023-02-27
申请人： Adamed Pharma S.A.
IPC分类号： A61K31/439 , A61P25/34 , A61K9/08 , A61K47/02
CPC分类号： A61P25/34 , A61K47/02 , A61K9/006 , A61K31/439 , A61K9/08
摘要： The present invention relates to a stabilized composition with significantly improved shelf-life stability. More particularly, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound. The present invention relates also to a use of at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound for the stabilization of a liquid aqueous pharmaceutical composition comprising cytisine.
-
公开(公告)号：EP3609493B1
公开(公告)日：2024-05-15
申请号：EP18716578.2
申请日：2018-04-03
IPC分类号： A61K31/4178 , A61K31/4164 , A61K31/7048 , A61K45/06 , A61K9/00 , A61K9/20 , A61K47/06 , A61P31/04
CPC分类号： A61K9/0034 , A61K45/06 , A61K47/06 , A61K9/2018 , A61K31/4164 , A61K31/4178 , A61K31/7048 , A61P31/04 , A61K9/06 , A61K9/1617 , A61P13/04
-
公开(公告)号：EP3755688B1
公开(公告)日：2023-06-14
申请号：EP19706271.4
申请日：2019-02-20
IPC分类号： C07D209/10 , C07D235/10 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61K31/496
-
-
公开(公告)号：EP3454838A1
公开(公告)日：2019-03-20
申请号：EP17723657.7
申请日：2017-05-07
申请人： Adamed Pharma S.A.
发明人： CIEPLUCHA, Agnieszka
CPC分类号： A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2077 , A61K31/397 , A61K31/505 , A61K45/06 , A61P3/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising rosuvastatin and ezetimibe for oral administration in the form of a blend of a first component comprising rosuvastatin or a pharmaceutically acceptable salt thereof, wherein the component is dry-granulated, a second component comprising ezetimibe or a pharmaceutically acceptable salt thereof, wherein the component is wet-granulated, and an optionally extragranular phase component, characterized in that the pharmaceutical composition is free from any rosuvastatin stabilizers, and d 90 value for granules of the first component is 800 µm or less. The invention relates also to an uncoated tablet comprising the composition, and a method of manufacturing the composition.
-
公开(公告)号：EP2934488B1
公开(公告)日：2018-10-17
申请号：EP13826632.5
申请日：2013-12-19
申请人： Adamed Pharma S.A.
发明人： CIEPLUCHA, Agnieszka
IPC分类号： A61K9/16 , A61K9/20 , A61K31/4184 , A61K31/4422
CPC分类号： A61K31/4184 , A61K9/1641 , A61K9/2077 , A61K31/4422 , A61K2300/00
摘要： A combination pharmaceutical composition comprising candesartan cilexetil and amiodipine or a pharmaceutically acceptable salt thereof, a process for the preparation of such composition and unit dosage form comprising such a composition. The composition consists of a granulate containing candesartan cilexetil, polyethylene glycol and other excipients, wherein the weight ratio of candesartan cilexetil to polyethylene glycol is in the range from 5: 1 to 2: 1, and extragranular phase of powder blend comprising amiodipine or a pharmaceutically acceptable salt thereof and excipients. The composition is prepared by mixing the granulate prepared by wet granulation and extragranular phase.
-
公开(公告)号：EP3740492B1
公开(公告)日：2022-03-02
申请号：EP19701777.5
申请日：2019-01-09
发明人： FEDER, Marcin , MAZUR, Maria , KALINOWSKA, Iwona , JASZCZEWSKA-ADAMCZAK, Joanna , LEWANDOWSKI, Wojciech , WITKOWSKI, Jakub , JELEN, Sabina , WOS-LATOSI, Katarzyna
IPC分类号： C07D487/10 , A61K31/407 , A61P35/00 , A61P37/00
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.016 秒)
